Skip to main content
. 2015 Apr 6;112(16):5225–5230. doi: 10.1073/pnas.1422998112

Fig. 3.

Fig. 3.

Edaravone ameliorates amyloid deposition in APP/PS1 mice. (A and D) Congo red staining and 6E10 immunohistochemical staining in the prevention (A) and treatment (D) experiments. Insets show the representative plaque at higher magnification. (Scale bar, 1 mm.) (B and E) Comparison of Congo red- or 6E10-positive plaques in the neocortex (NC) and hippocampus (HC) in the prevention (B) or treatment (E) experiments. (C and F) ELISA of Aβ40 and Aβ42 in TBS, SDS, and formic acid (FA) fraction of brain homogenates in the prevention (C) or treatment (F) experiments. (G) Cerebral amyloid angiopathy (CAA) was visualized using double immunofluorescence of 1a4 (smooth muscle actin antibody) and 6E10 (Aβ antibody) and scored according to the four-level scale for the severity of CAA. [Scale bar, 20 (Upper) and 5 μm (Lower).] (H) Comparison of CAA scores. *P < 0.05, **P < 0.01 (Student t test). Error bar, SEM.